Long-term outcome in patients with recurrent malignant glioma treated with perillyl alcohol inhalation

Anticancer Research

Volumn 33, Issue 12, 2013, Pages 5625-5631

  Da Fonseca, Clovis O ^a   Teixeira, Raphael M ^b   Silva, Júlio Cesar T ^c   Fischer, Juliana De Saldanha Da Gama ^d   Meirelles, Osório C ^e   Landeiro, Jose Alberto ^a   Quirico Santos, Thereza ^b  

^a HOSPITAL UNIVERSITÁRIO ANTÔNIO PEDRO   (Brazil)

^b FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^c Ipanema Federal Hospital   (Brazil)

^d INSTITUTO CARLOS CHAGAS   (Brazil)

^e FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

GBM; Glioblastoma multiforme; Glioma; Intranasal administration; Perillyl alcohol; Phase II trial

Indexed keywords

ANTINEOPLASTIC AGENT; PERILLYL ALCOHOL;

ADULT; AGED; ARTICLE; ASTROCYTOMA; BEHAVIOR DISORDER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; COGNITIVE DEFECT; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SAFETY; EPISTAXIS; FEMALE; GLIOBLASTOMA; HEADACHE; HEMIPARESIS; HUMAN; HUMAN TISSUE; LANGUAGE DISABILITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MENTAL DISEASE; MIDDLE AGED; NOSE DISEASE; OLIGODENDROGLIOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEIZURE; SOMNOLENCE; STEREOTACTIC BIOPSY; TOPOGRAPHY; TUMOR BIOPSY; TUMOR RECURRENCE; TUMOR VOLUME; YOUNG ADULT;

EID: 84891424146     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Adamson DC, Rasheed BA, McLendon RE and Bigner DD: Central nervous system. Cancer Biomark 9: 193-210, 2010.
2. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, DiPatre P, Burkhard C, Schuler D, Probst-Hensch N, Maiorka P, Baeza N, Pisani P, Yonekawa Y, Yasargil M, Lutolf U and Kleihues P: Genetic pathways to glioblastoma: a population-based study. Cancer Res 64: 6892-6899, 2004.
3. Hoelzinger DB, Demuth T and Berens ME: Autocrine Factors That Sustain Glioma Invasion and Paracrine Biology in the Brain Microenvironment. Journal of the National Cancer Institute 99: 1583-1593, 2007.
4. Clarke J, Penas C, Pastori C, Komotar RJ, Bregy A, Shah AH, Wahlestedt C and Ayad NG: Epigenetic pathways and glioblastoma treatment. Epigenetics 8: 785-795, 2013.
5. Minniti G, Scaringi C, De Sanctis V, Lanzetta G, Falco T, Di Stefano D, Esposito V and Enrici RM: Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas. J Neurooncol 111: 187-194, 2012.
6. Zhang J, Stevens MF and Bradshaw TD: Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol 5: 102-114, 2012.
7. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM and Hayes DN: Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110, 2010.
8. Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG and Parada LF: A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488: 522-526, 2012.
9. Nigro JM, Misra A, Zhang L, Smirnov I, Colman H, Griffin C, Ozburn N, Chen M, Pan E, Koul D, Yung WK, Feuerstein BG and Aldape KD: Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res 65: 1678-1686, 2005.
10. Lassman AB and Holland EC: Incorporating molecular tools into clinical trials and treatment for gliomas? Curr Op Neurol 20: 708-711, 2007.
11. Karp JE and Lancet JE: Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies. Cancer Invest 25: 484-494, 2007.
12. Duelund L, Amiot A, Fillon A and Mouritsen OG: Influence of the Active Compounds of Perilla frutescens Leaves on Lipid Membranes. Journal of Natural Products 75: 160-166, 2012.
13. Wiseman DA, Werner SR and Crowell PL: Cell Cycle Arrest by the Isoprenoids Perillyl Alcohol, Geraniol, and Farnesol Is Mediated by p21 Cip1 and p27 Kip1 in Human Pancreatic Adenocarcinoma Cells. Journal of Pharmacology and Experimental Therapeutics 320: 1163-1170, 2007.
14. Bailey HH, Attia S, Love RR, Fass T, Chappell R, Tutsch K, Harris L, Jumonville A, Hansen R, Shapiro GR and Stewart JA: Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer. Cancer Chemother Pharmacol 62: 149-157, 2008.
15. Yeruva L, Pierre KJ, Elegbede A, Wang RC and Carper SW: Perillyl alcohol and perillic acid induced cell cycle arrest and apoptosis in non small cell lung cancer cells. Cancer Letters 257: 216-226, 2007.
16. Holstein SA and Hohl RJ: Monoterpene regulation of Ras and Ras-related protein expression. J Lipid Res 44: 1209-1215, 2003.
17. Mo H and Elson CE: Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med (Maywood) 229: 567-585, 2004.
18. Cho HY, Wang W, Jhaveri N, Torres S, Tseng J, Leong MN, Lee DJ, Goldkorn A, Xu T, Petasis NA, Louie SG, Schonthal AH, Hofman FM and Chen TC: Perillyl alcohol for the treatment of temozolomide-resistant gliomas. Mol Cancer Ther 11: 2462-2472, 2012.
19. Sundin T, Peffley DM, Gauthier D and Hentosh P: The isoprenoid perillyl alcohol inhibits telomerase activity in prostate cancer cells. Biochimie 94: 2639-2648, 2012.
20. Caruso G, Caffo M, Alafaci C, Raudino G, Cafarella D, Lucerna S, Salpietro FM and Tomasello F: Could nanoparticle systems have a role in the treatment of cerebral gliomas? Nanomedicine 7: 744-752, 2011.
21. Da Fonseca CO, Schwartsmann G, Fischer J, Nagel J, Futuro D, Quirico-Santos T and Gattass CR: Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas. Surg Neurol 70: 259-266, 2008.
22. Da Fonseca CO, Simao M, Lins IR, Caetano RO, Futuro D and Quirico-Santos T: Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma. J Cancer Res Clin Oncol 137: 287-293, 2011.
23. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109, 2007.
24. Da Fonseca CO, Silva JT, Lins IR, Simao M, Arnobio A, Futuro D and Quirico-Santos T: Correlation of tumor topography and peritumoral edema of recurrent malignant gliomas with therapeutic response to intranasal administration of perillyl alcohol. Invest New Drugs 27: 557-564, 2009.
25. Dhuria SV, Hanson LR and Frey WH: Intranasal delivery to the central nervous system: Mechanisms and experimental considerations. Journal of Pharmaceutical Sciences 99: 1654-1673, 2010.
26. Pardeshi CV and Belgamwar VS: Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting. Expert Opinion on Drug Delivery 10: 957-972, 2013.
27. De Palma M and Hanahan D: The biology of personalized cancer medicine: Facing individual complexities underlying hallmark capabilities. Molecular Oncology 6: 111-127, 2012.
28. Bellail AC, Hunter SB, Brat DJ, Tan C and Van Meir EG: Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. The International Journal of Biochemistry & Cell Biology 36: 1046-1069, 2004.
29. Moller-Hartmann W, Herminghaus S, Krings T, Marquardt G, Lanfermann H, Pilatus U and Zanella F: Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology 44: 371-381, 2002.
30. Server A, Josefsen R, Kulle B, Maehlen J, Schellhorn T, Gadmar O, Kumar T, Haakonsen M, Langberg CW and Nakstad PH: Proton magnetic resonance spectroscopy in the distinction of high-grade cerebral gliomas from single metastatic brain tumors. Acta Radiol 51: 316-325, 2010.
31. Esteller M: Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br J Cancer 94: 179-183, 2006.
32. Di Vinci A, Casciano I, Marasco E, Banelli B, Ravetti GL, Borzi L, Brigati C, Forlani A, Dorcaratto A, Allemanni G, Zona G, Spaziante R, Gohlke H, Gardin G, Merlo DF, Mantovani V and Romani M: Quantitative methylation analysis of HOXA3, 7, 9, and 10 genes in glioma: association with tumor WHO grade and clinical outcome. J Cancer Res Clin Oncol 138: 35-47, 2012.